Search - tctmd.com

Displaying 561 - 580 of 725

Sort: Relevancy | Date

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

News Conference News TCT 2015

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

October 14, 2015

Presentation TCT 2015

TCT 77: Risk and Benefits of Triple Therapy in Patients Undergoing Percutaneous Coronary Stent Implantation Requiring Chronic Oral Anticoagulation A Meta-analysis of 12 Trials

Presenter: Lisa K. Jennings, Neal S. Kleiman, Lucia Barbieri

October 13, 2015

Presentation TCT 2015

The Clinical Impact of Stroke With 2 Preventative Strategies: LAA Closure vs Chronic Oral Anticoagulation

Presenter: Reda Ibrahim, Matthew J. Price, Vivek Y. Reddy

October 11, 2015

Presentation TCT 2015

Debate: Is LAA Closure an Alternative to Oral Anticoagulation in Low Bleeding Risk Patients? Yes, LAA Closure Is at Least as Good as Oral Anticoagulation!

Presenter: Reda Ibrahim, Matthew J. Price, Saibal Kar

October 11, 2015

Presentation TCT 2015

Debate: Is LAA Closure an Alternative to Oral Anticoagulation in Low Bleeding Risk Patients? No, It Should Be Limited to Anticoagulation Contraindicated Patients!

Presenter: Reda Ibrahim, Matthew J. Price, Jai-Wun Park

October 11, 2015

News Conference News TCT 2015

Use of LAA Occlusion in Low-Risk Patients Debated

Todd Neale

October 11, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

肺栓塞发作后，二级抗凝效果未持续

L.A. McKeown

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

Presentation

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Presenter: Francis Couturaud

July 10, 2015

News Daily News

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Yael L. Maxwell

July 10, 2015

News Daily News

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Yael L. Maxwell

July 10, 2015

News Daily News

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

L.A. McKeown

July 08, 2015

News Daily News

Statement on LAA Closure Highlights Key Issues for Growing Field

July 02, 2015

Advertisement

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

TCT 77: Risk and Benefits of Triple Therapy in Patients Undergoing Percutaneous Coronary Stent Implantation Requiring Chronic Oral Anticoagulation A Meta-analysis of 12 Trials

The Clinical Impact of Stroke With 2 Preventative Strategies: LAA Closure vs Chronic Oral Anticoagulation

Debate: Is LAA Closure an Alternative to Oral Anticoagulation in Low Bleeding Risk Patients? Yes, LAA Closure Is at Least as Good as Oral Anticoagulation!

Debate: Is LAA Closure an Alternative to Oral Anticoagulation in Low Bleeding Risk Patients? No, It Should Be Limited to Anticoagulation Contraindicated Patients!

Use of LAA Occlusion in Low-Risk Patients Debated

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

肺栓塞发作后，二级抗凝效果未持续

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

Statement on LAA Closure Highlights Key Issues for Growing Field

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content